Possible Protective Effect of Low Dose of Papaverine on ANIT Induce Cholestasis in Rat
DOI:
https://doi.org/10.31351/vol32issSuppl.pp118-126Keywords:
intrahepatic cholestasis,ANIT,papaverineAbstract
Abstract
Intrahepatic cholestasis is clinical syndrome which cause either by defect in synthesis or bile acid flow, the pathophysiology of cholestasis is complicated by a number of variables, including oxidative stress, inflammatory response, and dysregulation of bile acid transporter . Rats, mice, and guinea pigs were utilized as experimental animals, and ANIT was administered to them in order to create a model that closely resembled intrahepatic cholestasis in human. This study examined the protective effects of papaverine, a non-narcotic opium alkaloid derived from papaver somniferum and discovered as an FXR agonist, on cholestasis in rats induced by alpha-naphthylisothiocyanate (ANIT). Rats utilized in this study divided into 3 groups (10 rats per each groups), group I (control) or vehicle group rat administered corn oil (1ml/kg) once daily 48 hour before sacrifice group II rats orally administered alpha-naphthylisothiocyanate (ANIT) 100mg/kg single dose 48hour before sacrifice group III rats administered 100mg/kg papaverine orally for 7 consecutive days and at day 5 rat administered alpha-naphthylisothiocyanate (ANIT) The results showed that papaverine treatment decreased alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, total bile acid, as well as increased antioxidant enzyme GPX and decreased MDA and inflammatory mediators tumor necrosis factor TNF- and interleukin IL1-β. In conclusion, papaverine may have a protective effect to alleviate ANIT-induced cholestasis and may be a therapeutic target to treat cholestasis.
How to Cite
Publication Dates
References
Zalzala MH, Kareem VS. The Safranal Effect against Cyclophosphamide-Induced Liver Injury. Iraqi Journal of Pharmaceutical Sciences. 2021 Dec 11;30(2):208-13.
Ahmad HA, Kathem SH. Thymoquinone Attenuates Immune Mediated Liver Injury Induced by Concanavalin A in Mice. Iraqi Journal of Pharmaceutical Sciences. 2021 Dec 9;30(2):50-7.
Bertolini A, Fiorotto R, Strazzabosco M. Bile acids and their receptors: Modulators and therapeutic targets in liver inflammation. InSeminars in immunopathology 2022 Jul (Vol. 44, No. 4, pp. 547-564). Berlin/Heidelberg: Springer Berlin Heidelberg.
Onofrio FQ, Hirschfield GM. The pathophysiology of cholestasis and its relevance to clinical practice. Clinical liver disease. 2020 Mar;15(3):110.
Chen L, Wei S, Liu H, Li J, Jing M, Tong Y, Li R, Wen J, Zhan H, Zhao Y. Paeoniflorin protects against ANIT-induced cholestatic liver injury in rats via the activation of SIRT1-FXR signaling pathway. Evidence-Based Complementary and Alternative Medicine. 2021 Sep 2;2021.
Sultana H, Komai M, Shirakawa H. The Role of Vitamin K in Cholestatic Liver Disease. Nutrients. 2021 Aug;13(8):2515.
Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Digestive diseases. 2010;28(1):220-4.
van de Wiel SM, Bijsmans IT, van Mil SW, van de Graaf SF. Identification of FDA-approved drugs targeting the Farnesoid X Receptor. Scientific reports. 2019 Feb 18;9(1):1-1
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Iraqi Journal of Pharmaceutical Sciences ( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
This work is licensed under a Creative Commons Attribution 4.0 International License.